Workflow
Paxlovid
icon
Search documents
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
ZACKS· 2025-07-03 13:51
Key Takeaways PFE has traded above its 50-day SMA since the end of May, marking a short-term bullish trend. Pfizer's new products and Seagen deal are driving growth despite falling COVID sales and patent expirations. PFE trades below its 5-year average P/E, offering value amid high dividends and cost-cutting efforts.Pfizer (PFE) has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since the end of May, the stock has been trading above its 50-da ...
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July
The Motley Fool· 2025-07-03 07:51
Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer.For more than a century, Wall Street has been a bona fide wealth-creating machine. Though other asset classes, including bonds, commodities, and real estate, have also delivered positive long-term returns, none of these other investments has come particularly close to matching the average annual return of stocks over the last 100 years.With thousands of publicly traded companies and exchange-tra ...
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
ZACKS· 2025-06-24 15:26
Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...
晶泰控股20250616
2025-06-16 15:20
晶泰控股 20250616 摘要 晶泰控股通过 AI 和机器人技术赋能生物医药及材料分子的发现,已与辉 瑞、礼来等 17 家全球前二十大药企建立合作,商业模式涵盖研发服务 费、临床里程碑收费和销售分成,辉瑞新冠口服药 Paxlovid 即为成功案 例。 公司将 AI 加机器人技术拓展至新材料、化妆品和保健品领域,研发周期 较短,变现周期更快。与中石化上海实验室、广东中医药大学等合作项 目已落地并确认收入,并计划将具有生发效果的分子打造成化妆品产品。 晶泰控股拥有全球领先的大规模机器人实验室,用于化学合成实验,积 累标准化、高通量、高质量的数据,对 AI 算法提升至关重要,加速药物 发现和新材料领域的进展。 公司正在打造正确且高效的数据收集工具,以此作为未来十年的护城河, 数据是垂直领域 AI 模型的核心壁垒。与石药相比,公司在自动化合成和 真实世界实验数据方面具有优势,但需提升分子设计能力。 近期国际上,美国 FDA 提出未来使用 AI 取代动物测试,并调低美国药 物价格参照中国 NMPA 标准,对 AI 制药行业是重大利好。Isomobix 和 DeepMind 等合作公告也显示出行业发展的积极趋势。 Q& ...
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
ZACKS· 2025-06-12 15:26
Key Takeaways PFE's non-COVID revenues are rising, fueled by new drugs, key in-line products and Seagen acquisition. The Seagen deal added four ADCs to PFE's oncology portfolio, boosting revenues in 2024 and early 2025. PFE shares trade at a forward P/E of 7.97, well below the industry average and its 5-year historical mean.With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenue ...
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
ZACKS· 2025-06-09 15:20
Key Takeaways PFE stock is down 10.7% YTD, underperforming its industry, sector, and the broader market. COVID product sales are falling, but oncology drugs and Seagen assets are boosting top-line growth. PFE trades well below peers in terms of valuation and offers a 7.4% dividend yield with rising EPS estimates.Pfizer’s (PFE) stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below ...
Should You Buy Pfizer Stock Right Now?
The Motley Fool· 2025-06-07 10:30
Core Viewpoint - Pfizer is a pharmaceutical company with solid growth potential and a high dividend yield, making it a stock worth considering for investment [1][6]. Company Overview - Pfizer has a market value of approximately $133 billion and has been in operation since 1849, offering multiple treatments and a robust pipeline of products [3]. - The company currently has 108 candidates in its pipeline, with 47 in phase 1, 28 in phase 2, and 30 in phase 3, focusing significantly on oncology and various vaccines [4]. Current Products - Major medications include the COVID-19 vaccine, Paxlovid, Prevnar, Ibrance, and Xtandi [5]. Investment Considerations Reasons to Invest - The stock offers a dividend yield of 7.3%, generating around $730 for every $10,000 invested, with a commitment to maintain and grow this dividend over time [6][9]. - Pfizer's valuation is low, with a forward-looking P/E ratio of 8, below its five-year average of 10, and a price-to-sales ratio of 2.1, lower than its five-year average of 3.1 [11]. - The company has strong growth prospects, particularly in oncology, bolstered by the acquisition of Seagen for $43 billion [11]. Reasons Against Investment - The payout ratio is 122%, indicating that the company is paying out more than its earnings in dividends, which may not be sustainable [11]. - Pfizer has experienced average annual losses of 18.6% over the past three years, with revenue declining from $100.3 billion in 2022 to $63.6 billion in 2024 [11]. - Several key products are losing patent protection, and concerns have arisen regarding the safety of its weight-loss drug candidate [11]. - Ongoing tariff wars and government efforts to lower drug costs may pose additional challenges for the company [11].
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
The Motley Fool· 2025-06-05 07:34
Group 1: Pfizer - Pfizer's stock has decreased by approximately 62% from its pandemic highs, yet it offers a high dividend yield of 7.3% [4] - The company's adjusted earnings per share fell from $6.58 in 2022 to $3.11 last year due to declining demand for COVID-19 vaccines and treatments [4][5] - Pfizer anticipates a 6.8% decline in adjusted earnings for the current year, with a projected low of $2.80 per share, which is sufficient to support its annual dividend of $1.72 [5] - The drug Eliquis, which accounts for 14% of Pfizer's revenue, is expected to face competition from generics starting in 2028 [6] - Despite facing patent cliffs, Pfizer has a strong development pipeline, with over a dozen FDA approvals last year, indicating potential for continued dividend growth [7] Group 2: Prologis - Prologis has capitalized on the surge in e-commerce demand, becoming the largest real estate investment trust (REIT) available to everyday investors [8] - The stock has declined by about 12% from its March peak, currently offering a 3.7% yield [8] - Prologis has increased its dividend by 11.7% annually over the past five years, suggesting potential for double-digit yield on cost for investors in less than a decade [9] - Major customers include Amazon, Home Depot, and FedEx, but these tenants only account for 8.2% of total rent payments, showcasing strong diversification [9] - Prologis holds an A2 rating from Moody's and an A rating from S&P Global, with a low average interest rate of 3.1% on its debts [10] - The company can offer competitive rates to smaller competitors and is positioned for continued growth by acquiring and leasing back logistics real estate [11] Group 3: Investment Comparison - Pfizer offers a nearly double yield compared to Prologis, but its dividend growth rate is less than half that of Prologis [12] - For investors nearing retirement, Pfizer may be appealing, while Prologis is suggested as a better option for income-seeking investors [12]
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
The Motley Fool· 2025-06-05 07:06
A volatile stock market represents an ideal opportunity for long-term investors to pounce.It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related uncertainty pushed the Nasdaq Composite into its first bear market in three years, and weighed the S&P 500 down to near-bear market territory.Historic ...
Terrible News for Pfizer Stock Investors
The Motley Fool· 2025-06-01 13:15
Core Insights - Pfizer has faced significant challenges over the past three years, with a 56% decline in stock price since 2022, and efforts to improve have been insufficient [1] - The company's revenue from its coronavirus portfolio has sharply decreased as the pandemic recedes, with combined revenue from Paxlovid and Comirnaty at $11.1 billion in 2024 [2] - Recent regulatory changes in the U.S. will limit access to the COVID-19 vaccine, impacting Pfizer's revenue generation capabilities [5][6] Financial Performance - Pfizer's total revenue reached $63.6 billion, a 7% increase year-over-year, with a 12% growth when excluding coronavirus products [3] - Sales from Paxlovid and Comirnaty accounted for approximately 17.5% of total revenue, indicating their critical role in the company's financial health [3] - The U.S. market is crucial for Pfizer, with $2.004 billion in revenue from the U.S. coronavirus vaccine market last year, representing about 37% of Comirnaty's total revenue [7] Regulatory Impact - The FDA's new guidelines restrict COVID-19 vaccine recommendations to seniors and high-risk individuals, which could reduce the overall market size for vaccines [5][6] - While the changes may weaken the coronavirus franchise, they are not expected to significantly impact Paxlovid sales [7][8] Strategic Moves - Pfizer has made strides to enhance its pipeline, including a $1.25 billion upfront payment for the licensing of a promising cancer medicine, SSGJ-707 [10] - The company is well-positioned for potential regulatory wins in oncology, supported by a robust pipeline and extensive experience in drug development [11] - Pfizer is focused on reducing expenses and costs, with plans to continue this strategy until 2027 [11] Future Outlook - Despite recent challenges, Pfizer's past success in the coronavirus market and ongoing investments in its pipeline suggest potential for future returns [12]